TX SB3005

Directs the Department of State Health Services to conduct a study on psychedelic therapies—specifically MDMA, psilocybin, and ketamine—for treating PTSD, depression, and co-occurring conditions

Requires the department to consult with Baylor College of Medicine and the Center for Psychedelic Research and Therapy at Dell Medical School at UT Austin

Study must review clinical trials, current literature, and FDA actions related to psychedelic therapies, as well as evaluate treatment guidelines and recommend best practices for providers

Must assess patient access barriers including provider availability, affordability, training, licensure, and regulatory requirements, and recommend actions to ensure access following FDA approval

Report due to the governor, lieutenant governor, speaker of the house, and relevant committee chairs by December 1, 2026; the Act expires September 1, 2027